PE20090449A1 - Agonistas de receptor acoplado a proteina g gpr119 de piridona - Google Patents

Agonistas de receptor acoplado a proteina g gpr119 de piridona

Info

Publication number
PE20090449A1
PE20090449A1 PE2008001197A PE2008001197A PE20090449A1 PE 20090449 A1 PE20090449 A1 PE 20090449A1 PE 2008001197 A PE2008001197 A PE 2008001197A PE 2008001197 A PE2008001197 A PE 2008001197A PE 20090449 A1 PE20090449 A1 PE 20090449A1
Authority
PE
Peru
Prior art keywords
gpr119
protein
piridone
receptor agonists
coupled receptor
Prior art date
Application number
PE2008001197A
Other languages
English (en)
Spanish (es)
Inventor
Dean A Wacker
Karen A Rossi
Ying Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20090449A1 publication Critical patent/PE20090449A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PE2008001197A 2007-07-17 2008-07-16 Agonistas de receptor acoplado a proteina g gpr119 de piridona PE20090449A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17

Publications (1)

Publication Number Publication Date
PE20090449A1 true PE20090449A1 (es) 2009-04-18

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001197A PE20090449A1 (es) 2007-07-17 2008-07-16 Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE2008001196A PE20090888A1 (es) 2007-07-17 2008-07-16 Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008001196A PE20090888A1 (es) 2007-07-17 2008-07-16 Compuestos heterociclicos como agentes moduladores del receptor acoplado a la proteina g gpr119

Country Status (26)

Country Link
US (6) US8003796B2 (OSRAM)
EP (2) EP2170864B1 (OSRAM)
JP (3) JP5318867B2 (OSRAM)
KR (2) KR20100051814A (OSRAM)
CN (3) CN101801956B (OSRAM)
AR (2) AR067569A1 (OSRAM)
AT (2) ATE524460T1 (OSRAM)
AU (2) AU2008276057B2 (OSRAM)
BR (2) BRPI0815097A2 (OSRAM)
CA (2) CA2693444A1 (OSRAM)
CL (2) CL2008002110A1 (OSRAM)
CO (1) CO6160315A2 (OSRAM)
CY (2) CY1112151T1 (OSRAM)
DK (2) DK2170864T3 (OSRAM)
EA (2) EA018709B1 (OSRAM)
ES (2) ES2378914T3 (OSRAM)
HR (2) HRP20110806T1 (OSRAM)
IL (1) IL228120A0 (OSRAM)
NZ (2) NZ582661A (OSRAM)
PE (2) PE20090449A1 (OSRAM)
PL (2) PL2173737T3 (OSRAM)
PT (2) PT2173737E (OSRAM)
SI (2) SI2173737T1 (OSRAM)
TW (2) TW200904439A (OSRAM)
WO (2) WO2009012275A1 (OSRAM)
ZA (2) ZA201000151B (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588867A1 (en) * 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
JP5318867B2 (ja) * 2007-07-17 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JP2011528365A (ja) * 2008-07-16 2011-11-17 シェーリング コーポレイション Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
JP2011528369A (ja) * 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP2012520868A (ja) * 2009-03-20 2012-09-10 ファイザー・インク ３−オキサ−７−アザビシクロ［３．３．１］ノナン
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102933576A (zh) 2010-04-08 2013-02-13 百时美施贵宝公司 作为gpr119调节剂的嘧啶基哌啶基氧基吡啶酮类似物
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
DK2625177T3 (en) 2010-10-08 2015-10-12 Cadila Healthcare Ltd New GPR 119 agonists
JP5848775B2 (ja) 2010-12-06 2016-01-27 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド 置換ピリジノンピリジニル化合物
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014077235A1 (ja) * 2012-11-13 2014-05-22 大正製薬株式会社 ２－ピリドン化合物
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
JP6699909B2 (ja) 2013-06-07 2020-05-27 アクラリス セラピューティクス，インコーポレイテッド メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
EP3010893B1 (de) 2013-06-20 2019-10-02 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
BR112015031155A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas
US9783509B2 (en) 2013-07-08 2017-10-10 Bayer Cropscience Aktiengesellschaft Six-membered C-N-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest conrol agents
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
CA2960791C (en) 2014-09-11 2023-03-14 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016130652A1 (en) 2015-02-10 2016-08-18 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
AU2021244609A1 (en) 2020-03-27 2022-09-15 Aclaris Therapeutics, Inc. Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
WO2000039102A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
US6586418B2 (en) 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
WO2002044362A1 (en) 2000-12-01 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. Method of screening remedy for diabetes
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP4164031B2 (ja) * 2002-02-14 2008-10-08 ファルマシア コーポレーション Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
US20070066590A1 (en) 2003-02-24 2007-03-22 Jones Robert M Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN100509798C (zh) * 2003-07-11 2009-07-08 艾尼纳制药公司 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
US7132426B2 (en) * 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005025504A2 (en) 2003-09-12 2005-03-24 Kemia, Inc. Modulators of calcitonin and amylin activity
EP1741703A4 (en) * 2004-03-05 2009-11-25 Banyu Pharma Co Ltd pyridone
GB2427551B (en) 2004-03-17 2007-05-30 7Tm Pharma As Y4 selective receptor agonists for therapeutic interventions
BRPI0510599A (pt) 2004-05-03 2007-11-20 Hoffmann La Roche compostos, processo para a preparação dos mesmos, composição farmacêutica, uso de um composto, e método para o tratamento e a profilaxia de doenças
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006262425C1 (en) 2005-06-23 2012-06-21 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
US20090325924A1 (en) * 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
JP5318867B2 (ja) 2007-07-17 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト

Also Published As

Publication number Publication date
ATE524460T1 (de) 2011-09-15
ES2378914T3 (es) 2012-04-19
CL2008002111A1 (es) 2008-10-24
US20110245227A1 (en) 2011-10-06
BRPI0814428A2 (pt) 2015-01-06
CL2008002110A1 (es) 2008-10-24
CN101801957A (zh) 2010-08-11
ZA201000326B (en) 2011-03-30
ES2371515T3 (es) 2012-01-04
CO6160315A2 (es) 2010-05-20
US8003796B2 (en) 2011-08-23
WO2009012275A1 (en) 2009-01-22
DK2173737T3 (da) 2012-05-07
EP2170864A1 (en) 2010-04-07
US20090023702A1 (en) 2009-01-22
NZ582664A (en) 2012-03-30
AU2008276055B2 (en) 2013-01-31
EA016595B1 (ru) 2012-06-29
ZA201000151B (en) 2011-03-30
TW200904440A (en) 2009-02-01
US8178561B2 (en) 2012-05-15
KR20100051814A (ko) 2010-05-18
KR20100045471A (ko) 2010-05-03
JP5301539B2 (ja) 2013-09-25
AU2008276057B2 (en) 2013-01-31
PE20090888A1 (es) 2009-07-15
EP2170864B1 (en) 2011-09-14
PL2170864T3 (pl) 2012-02-29
US8232404B2 (en) 2012-07-31
CN103550218A (zh) 2014-02-05
WO2009012277A1 (en) 2009-01-22
PT2173737E (pt) 2012-03-19
EP2173737A1 (en) 2010-04-14
PL2173737T3 (pl) 2012-06-29
EA018709B1 (ru) 2013-10-30
BRPI0815097A2 (pt) 2018-07-24
SI2170864T1 (sl) 2012-04-30
HK1143136A1 (en) 2010-12-24
NZ582661A (en) 2012-03-30
HRP20110806T1 (hr) 2011-11-30
TW200904439A (en) 2009-02-01
CY1112751T1 (el) 2016-02-10
EA201000210A1 (ru) 2010-06-30
CN101801956B (zh) 2013-11-20
PT2170864E (pt) 2011-11-25
CY1112151T1 (el) 2015-12-09
JP2013237680A (ja) 2013-11-28
US20110190327A1 (en) 2011-08-04
CA2693444A1 (en) 2009-01-22
US7928230B2 (en) 2011-04-19
JP2010533726A (ja) 2010-10-28
IL228120A0 (en) 2013-09-30
CN101801956A (zh) 2010-08-11
AU2008276057A1 (en) 2009-01-22
JP5318867B2 (ja) 2013-10-16
US20090042919A1 (en) 2009-02-12
US20120232048A1 (en) 2012-09-13
ATE540945T1 (de) 2012-01-15
WO2009012275A9 (en) 2010-03-11
AR067569A1 (es) 2009-10-14
EP2173737B1 (en) 2012-01-11
DK2170864T3 (da) 2012-01-16
CA2693439A1 (en) 2009-01-22
HRP20120221T1 (hr) 2012-04-30
EA201000211A1 (ru) 2010-06-30
US20120258959A1 (en) 2012-10-11
AR067568A1 (es) 2009-10-14
SI2173737T1 (sl) 2012-05-31
AU2008276055A1 (en) 2009-01-22
HK1136298A1 (en) 2010-06-25
US8513424B2 (en) 2013-08-20
JP2010533727A (ja) 2010-10-28

Similar Documents

Publication Publication Date Title
PE20090449A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20121045A1 (es) Agonista de gpr119
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
PE20081659A1 (es) Agonistas de gpcr
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
AR077143A1 (es) Compuestos insecticidas
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
DK1725660T3 (da) Ekspressionskassetter med multiple promotorer til samtidig afgivelse af RNAi-midler
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20091527A1 (es) Derivados de piridazinona
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20090222A1 (es) Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
PE20110672A1 (es) 4-fenil-1-h-pirazoles insecticidas
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20090610A1 (es) Derivados de pirazol sustituidos
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20131377A1 (es) Triazina-oxadiazoles

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed